Major depressive disorder: Remission of associated symptoms

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Major depressive disorder (MDD) is a highly prevalent disease often associated with significant medical comorbidity. However, limited data are available examining the associated symptoms of MDD, especially the painful physical symptoms that frequently occur in patients. The presence of these physical symptoms greatly reduces a clinician's ability to recognize and diagnose MDD, ultimately leading to poor treatment outcome. While the treatment goal of MDD is complete remission of all symptoms and the patient's return to full-functioning capacity, if physical symptoms persist, the patient does not achieve functional recovery. Severe consequences have been associated with incomplete remission and residual symptoms, including greater disability and health care costs, plus the increased risk of relapse, morbidity, and mortality. In the treatment of MDD, the noradrenergic, serotonergic, and dopaminergic neural pathways have been found to be affected by depression. More specifically, these neural pathways may correlate with certain psychological and physical symptoms of depression. By studying the effects of antidepressant medications on specific neurotransmitters, antidepressant therapies could be matched to treat specific symptoms of depression. To achieve the goal of remission, clinicians must first determine the best rating method to identify and accurately evaluate the physical symptoms of depression in addition to the core mood symptoms. Therefore, further studies are needed to aid our assessment of physical symptoms and to meet the challenge of effectively matching treatments to a patient's specific symptoms.

Original languageEnglish (US)
Pages (from-to)27-32
Number of pages6
JournalJournal of Clinical Psychiatry
Volume67
Issue numberSUPPL. 6
StatePublished - 2006

Fingerprint

Major Depressive Disorder
Depression
Neural Pathways
Antidepressive Agents
Aptitude
Symptom Assessment
Therapeutics
Health Care Costs
Neurotransmitter Agents
Comorbidity
Psychology
Morbidity
Recurrence
Mortality

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Major depressive disorder : Remission of associated symptoms. / Trivedi, Madhukar H.

In: Journal of Clinical Psychiatry, Vol. 67, No. SUPPL. 6, 2006, p. 27-32.

Research output: Contribution to journalArticle

@article{a776b0df138f453a80f4cce684c96213,
title = "Major depressive disorder: Remission of associated symptoms",
abstract = "Major depressive disorder (MDD) is a highly prevalent disease often associated with significant medical comorbidity. However, limited data are available examining the associated symptoms of MDD, especially the painful physical symptoms that frequently occur in patients. The presence of these physical symptoms greatly reduces a clinician's ability to recognize and diagnose MDD, ultimately leading to poor treatment outcome. While the treatment goal of MDD is complete remission of all symptoms and the patient's return to full-functioning capacity, if physical symptoms persist, the patient does not achieve functional recovery. Severe consequences have been associated with incomplete remission and residual symptoms, including greater disability and health care costs, plus the increased risk of relapse, morbidity, and mortality. In the treatment of MDD, the noradrenergic, serotonergic, and dopaminergic neural pathways have been found to be affected by depression. More specifically, these neural pathways may correlate with certain psychological and physical symptoms of depression. By studying the effects of antidepressant medications on specific neurotransmitters, antidepressant therapies could be matched to treat specific symptoms of depression. To achieve the goal of remission, clinicians must first determine the best rating method to identify and accurately evaluate the physical symptoms of depression in addition to the core mood symptoms. Therefore, further studies are needed to aid our assessment of physical symptoms and to meet the challenge of effectively matching treatments to a patient's specific symptoms.",
author = "Trivedi, {Madhukar H.}",
year = "2006",
language = "English (US)",
volume = "67",
pages = "27--32",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "SUPPL. 6",

}

TY - JOUR

T1 - Major depressive disorder

T2 - Remission of associated symptoms

AU - Trivedi, Madhukar H.

PY - 2006

Y1 - 2006

N2 - Major depressive disorder (MDD) is a highly prevalent disease often associated with significant medical comorbidity. However, limited data are available examining the associated symptoms of MDD, especially the painful physical symptoms that frequently occur in patients. The presence of these physical symptoms greatly reduces a clinician's ability to recognize and diagnose MDD, ultimately leading to poor treatment outcome. While the treatment goal of MDD is complete remission of all symptoms and the patient's return to full-functioning capacity, if physical symptoms persist, the patient does not achieve functional recovery. Severe consequences have been associated with incomplete remission and residual symptoms, including greater disability and health care costs, plus the increased risk of relapse, morbidity, and mortality. In the treatment of MDD, the noradrenergic, serotonergic, and dopaminergic neural pathways have been found to be affected by depression. More specifically, these neural pathways may correlate with certain psychological and physical symptoms of depression. By studying the effects of antidepressant medications on specific neurotransmitters, antidepressant therapies could be matched to treat specific symptoms of depression. To achieve the goal of remission, clinicians must first determine the best rating method to identify and accurately evaluate the physical symptoms of depression in addition to the core mood symptoms. Therefore, further studies are needed to aid our assessment of physical symptoms and to meet the challenge of effectively matching treatments to a patient's specific symptoms.

AB - Major depressive disorder (MDD) is a highly prevalent disease often associated with significant medical comorbidity. However, limited data are available examining the associated symptoms of MDD, especially the painful physical symptoms that frequently occur in patients. The presence of these physical symptoms greatly reduces a clinician's ability to recognize and diagnose MDD, ultimately leading to poor treatment outcome. While the treatment goal of MDD is complete remission of all symptoms and the patient's return to full-functioning capacity, if physical symptoms persist, the patient does not achieve functional recovery. Severe consequences have been associated with incomplete remission and residual symptoms, including greater disability and health care costs, plus the increased risk of relapse, morbidity, and mortality. In the treatment of MDD, the noradrenergic, serotonergic, and dopaminergic neural pathways have been found to be affected by depression. More specifically, these neural pathways may correlate with certain psychological and physical symptoms of depression. By studying the effects of antidepressant medications on specific neurotransmitters, antidepressant therapies could be matched to treat specific symptoms of depression. To achieve the goal of remission, clinicians must first determine the best rating method to identify and accurately evaluate the physical symptoms of depression in addition to the core mood symptoms. Therefore, further studies are needed to aid our assessment of physical symptoms and to meet the challenge of effectively matching treatments to a patient's specific symptoms.

UR - http://www.scopus.com/inward/record.url?scp=33746054954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746054954&partnerID=8YFLogxK

M3 - Article

C2 - 16848674

AN - SCOPUS:33746054954

VL - 67

SP - 27

EP - 32

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - SUPPL. 6

ER -